1,721,352 research outputs found
Biomarker Analysis in Bo21015, a Phase Ii Randomised Study of First-Line Bevacizumab (Bev) Combined with Carboplatin-Gemcitabine (Cg) or Carboplatin-Paclitaxel (Cp) in Patients (Pts) with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Nscl
No full textClinical Characteristics and Outcomes of Lung Cancer with Pulmonary Embolism
No full textBackground: Cancer patients have a higher risk for thrombosis that is usually related to advanced stage and poor prognosis. This study aimed to identify the clinical picture and outcome of non-small cell lung cancer ( NSCLC) and small cell lung cancer (SCLC) patients with pulmonary embolism (PE). Patients and Methods: From 1996 to 2005, the clinical presentation of lung cancer patients with PE was evaluated. Their survival was compared with matched controls by log-rank test. Results: A total of 24 patients, 17 men ( 70.8%) and 7 women (median age: 62.5 years), were identified . Nineteen patients (79.2%) initially presented with advanced lung cancer ( 16 stage IV, 1 stage III-b NSCLC and 2 extensive-stage SCLC). Wells' clinical prediction score for PE only predicted moderate probability ( median: 5.25). In patients with PE, survival was significantly shorter than in matched control patients (243.5 vs. 327 days, p = 0.01). This difference was more significant when PE presented concomitant with cancer (p = 0.003) than when PE developed during cancer treatment (p = 0.206). Conclusions: PE is an important event in lung cancer patients which usually occurs in advanced disease and affects survival. In patients presenting PE at the initial diagnosis of cancer, the prognosis was the worst
Cryptogenic organizing pneumonia mimicking community-acquired pneumonia with acute respiratory failure: A case report
No full text
Small-cell Lung Carcinoma with the Initial Presentation of Otalgia and Hearing Impairment
No full textExtensively drug-resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features and outcomes
No full textRandomized, Placebo-Controlled, Phase Ii Study of Sequential Erlotinib and Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
No full textPurpose This study investigated whether sequential administration of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in unselected, chemotherapy-naive patients with advanced non-small- cell lung cancer (NSCLC). Patients and Methods Previously untreated patients (n = 154) with stage IIIB or IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned to receive erlotinib (150 mg/d) or placebo on days 15 to 28 of a 4-week cycle that included gemcitabine (1,250 mg/m(2) days 1 and 8) and either cisplatin (75 mg/m2 day 1) or carboplatin (5 x area under the serum concentration-time curve, day 1). The primary end point was nonprogression rate (NPR) at 8 weeks. Secondary end points included tumor response rate, NPR at 16 weeks, duration of response, progression-free survival (PFS), overall survival (OS), and safety. Results The NPR at 8 weeks was 80.3% in the gemcitabine plus cisplatin or carboplatin (GC)-erlotinib arm (n = 76) and 76.9% in the GC- placebo arm (n = 78). At 16 weeks, the NPR was 64.5% for GC - erlotinib versus 53.8% for GC-placebo. The response rate was 35. 5% for GC-erlotinib versus 24.4% for GC-placebo. PFS was significantly longer with GC-erlotinib than with GC- placebo(adjusted hazard ratio, 0.47 ; log-rank P = .0002; median, 29.4 v 23.4 weeks); this benefit was consistent across all clinical subgroups. There was no significant difference in OS. The addition of erlotinib to chemotherapy was well tolerated, with no increase in hematologic toxicity , and no treatment- related interstitial lung disease. Conclusion Sequential administration of erlotinib following gemcitabine/platinum chemotherapy led to a significant improvement in PFS. This treatment approach warrants further investigation in a phase III study
Comparison of OK-432 and Mitomycin C Pleurodesis for Malignant Pleural Effusion Due to Lung Cancer:a Randomized Trial
No full text- …
